International Psoriasis Council

Advancing Knowledge. Improving Care.

Diverse Skin Tones

CLOSING GAPS IN PSORIASIS CARE FOR DIVERSE SKIN TYPES

Project Description

The Diverse Skin Tones Working Group is dedicated to addressing unmet needs in psoriasis care for diverse skin tones. The group focuses on enhancing dermatologists’ ability to diagnose and treat psoriasis in individuals with diverse skin accurately and collaborates with organizations, including patient and dermatology associations, to promote equitable care.

In 2025, the group achieved two significant milestones: publishing Psoriasis in People With Skin of Color: An Evidence-Based Update in the International Journal of Dermatology and launching Visual Differences in Psoriasis on Diverse Skin Tones, a clinical education tool aimed at improving diagnostic accuracy and advancing equitable care for patients with diverse skin tones.

Looking ahead, the Diverse Skin Tones Working Group will continue developing educational tools and resources for clinicians while fostering collaborations with organizations such as the GPA, IFPA, and the Skin of Color Society.

Project Leaders

Mahira El Sayed Headshot

Mahira

El Sayed

,

MSc, MD

Ain Shams University

Cairo

,

Egypt

Chair

IPC Board Member
Murlidhar Rajagopalan Headshot

Murlidhar

Rajagopalan

,

MD

Apollo Hospitals

Chennai

,

India

Co-chair

IPC Councilor

Working Group Members

  • Andrew Alexis, United States
  • Nejib Doss, Tunisia
  • Maria-Angeliki Gkini, United Kingdom
  • Chris Griffiths, United Kingdom
  • Elise Kleyn, United Kingdom
  • Mark Lebwohl, United States
  • Angela Londoño, Colombia
  • Mohammad Rafiqul Mowla, Bangladesh
  • Mio Nakamura, United States
  • Junko Takeshita, United States
  • Vermén Verallo-Rowell, Philippines

View more resources on diverse skin.

[thrive_leads id='12021']

Subscribe to the IPC Newsletter

We believe that psoriasis patients, no matter where they live in the world, no matter how complex their symptoms, should have access to the best care available to them. Please join us in making this possible.

Name(Required)

What's New

First-Line Biologics in Psoriasis: Evidence from the BADBIR Cohort Study

In this IPC commentary, Matias Maskin examines evidence from the BADBIR registry demonstrating that first-line biologic therapy in moderate to severe psoriasis leads to faster skin clearance, improved quality of life, and a lower risk of comorbidities. The analysis challenges traditional step-up approaches and supports earlier, patient-centered treatment strategies.

Read More »

Recent Advances in Psoriasis: A Year in Review

In this Take Ten with IPC video, Dr. Leandro Leite discusses the most recent advances in psoriasis over the last year (March 2025 – March 2026). Topics include new guidelines, research, and recent studies.

WATCH NOW

Monday, April 6, 2026